How come not every patient with diabetes develops vascular complications?
In this medfyle
Expert commentary by Prof. Tsvetalina Tankova
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the Virtual EASD Annual Meeting 2021 and presented by:
Dr. Tiinamaija Tuomi
Helsinki University Hospital
Helsinki, Finland
Dr. Adam Tabák
University College London
London, UK
Prof. John Petrie
University of Glasgow
Glasgow, United Kingdom
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Prof. Tsvetalina Tankova, MF, PhD, DMedSc
Medical University - Sofia, Bulgaria
About the Expert
Prof. Tsvetalina Tankova, MF, PhD, DMedSc
Medical University - Sofia, Bulgaria
Tsvetalina Tankova, MD, PhD, DMedSc is Professor of Endocrinology, Head of the Department of Diabetology at the University Hospital of Endocrinology, Medical University, Sofia; Chair in Endocrinology and Vice Rector for International Integration and Project Funding at the Medical University, Sofia, Bulgaria. Specialist in Internal Medicine and Endocrinology. Master’s degree in Public Health and Healthcare Management. Has specialized at WHO Collaborating Center, University Hospital, Geneva, Switzerland; King's College Hospital, London, Oxford, Cambridge, UK; Steno Diabetes Center, Copenhagen, Denmark. Author of over 230 peer-reviewed publications; over 5000 citations in international journals; over 400 presentations at national and international meetings. h-index 26. Invited speaker at EASD postgraduate training courses in many countries.Serves as Editorial Board member and reviewer at a number of national and international journals. Secretary of the Bulgarian Society of Endocrinology since 2003. Member of the Expert Committee on Endocrinology at the Bulgarian Ministry of Health. Runs several national and international research projects on prediabetes, diabetes, obesity, metabolic syndrome, complications of diabetes.
Disclosures: Prof. Tankova received lecture fees from AstraZeneca, Lilly, Novartis, MSD, Servier, NovoNordisk, SANOFI, Boehringer Ingelheim, Worwag; Advisory Board member of Novartis, MSD, SANOFI, NovoNordisk, Boehringer Ingelheim, LifeScan, Lilly, Astra Zeneca, Worwag.
References
1. Sandholm N, Van Zuydam N, Ahlqvist E, et al. The Genetic Landscape of Renal Complications in Type 1 Diabetes. J Am Soc Nephrol. 2017;28(2):557-574.
2. Harjutsalo V, Katoh S, Sarti C, et al. Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes. 2004;53(9):2449-54.
3. van Zuydam NR, Ahlqvist E, Sandholm Net al. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes. 2018;67(7):1414-1427
4. Salem RM, Todd JN, Sandholm N, et al. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. J Am Soc Nephrol. 2019;30(10):2000-2016.
5. Forrest IS, Chaudhary K, Paranjpe I, et al. Genome-wide polygenic risk score for retinopathy of type 2 diabetes. Hum Mol Genet. 2021;30(10):952-960.
6. Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: a review of the epidemiologic evidence. Kidney Int. 2006;70(12):2074-84.
7. Lin JL, Lin-Tan DT, Yu CC, et al. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int. 2006;69(11):2049-56.
8. Anjana RM, Mohan V, Rangarajan S, et al. Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. Diabetes Care. 2020;43(12):3094-3101.
9. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215-229.
10. Liu G, Li Y, Hu Y, et al. Influence of Lifestyle on Incident Cardiovascular Disease and Mortality in Patients With Diabetes Mellitus. J Am Coll Cardiol. 2018;71(25):2867-2876.
11. Milenkovic T, Bozhinovska N, Macut D, et al. Mediterranean Diet and Type 2 Diabetes Mellitus: A Perpetual Inspiration for the Scientific World. A Review. Nutrients. 2021;13(4):1307.
12. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.
13. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446.
14. Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298-2307.
15. Wagner R, Heni M, Tabák AG, et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021;27(1):49-57.
